The G1T28‐04 clinical study conducted in patients with TNBC demonstrated that trilaciclib exhibits comparable efficacy regardless of CDK4/6 dependency, indicating that it does not interfere with the cytotoxic effects of chemotherapy on tumor cells [32]. This evidence concerns the gene CDK4 and neoplasm.